Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia [ID6519]

  • Awaiting development
  • GID-TA11649
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Obicetrapib or obicetrapib-ezetimibe within its marketing authorisation for treating
primary hypercholesterolaemia or mixed dyslipidaemia